All In Biotech

Drug Trial Radar · NCT04341116

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Last checked: Nov 19, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149

Actual

Start

Apr 11, 2020

Primary completion

Feb 7, 2022

Study completion Feb 7, 2022

Sponsor

Lead sponsor
I-Mab Biopharma US LimitedIndustry
Sponsor type
Industry
First posted
Apr 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of cytokines.

Conditions

  • Coronavirus Disease 2019 COVID-19

Interventions

  • TJ003234Drug

    patients receive a single infusion

  • PlaceboDrug

    patients receive a single infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at BaselineTime frame: Day 1 through Day 30

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas

    Little Rock, Arkansas

  • Olive View-UCLA Medical Center

    Sylmar, California

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • The GW Medical Faculty Associates

    Washington D.C., District of Columbia

  • University of Miami

    Miami, Florida

  • OSF Healthcare Saint Francis Medical Center

    Peoria, Illinois

  • Indiana University Health

    Indianapolis, Indiana

  • Medpharmics, LLC

    Metairie, Louisiana

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • University Medical Center of Southern Nevada

    Las Vegas, Nevada

  • UNM Hospitals

    Albuquerque, New Mexico

  • Houston Methodist Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.